Original analysis of Medicare Advantage denial patterns from a 500-plus provider dataset across 22 specialties. Why MA denials are surging, which CARC codes drive most of the volume, and what providers can do about it.
Medicare Advantage enrollment has crossed half of all eligible Medicare beneficiaries, and the denial economics that come with it are reshaping revenue cycles across every specialty. This report aggregates anonymized denial data from Revenue Synergy's active client base, isolates Medicare Advantage claims, and ranks the top denial drivers and specialty hotspots for 2026.
This report is built from anonymized aggregate data drawn from Revenue Synergy's active client base, covering more than 500 rendering providers across 22 distinct specialty cohorts. Claim-level and remittance-level data was captured continuously between January 1, 2025 and December 31, 2025. The dataset was filtered to Medicare Advantage primary claims only, identified by payer-of-record at the clearinghouse and confirmed via the patient's coverage segment in 837 transactions. Original Medicare and commercial claims were excluded from the MA cohort analysis but retained for the comparison benchmark cited throughout this report.
Denial reason codes were normalized from CARC and RARC fields on 835 remittance advice transactions. Where multiple CARCs were present on a single remit line, the leading code was attributed as the primary denial driver. RARC codes were used only as supporting context, not for primary attribution. All practice identifiers are stripped before aggregation, and no single client contributes more than 4 percent of the volume in any specialty cohort, preventing skew from outsized practices. Denial rate is calculated as the percentage of submitted claim lines that received an initial non-zero CARC adjustment, regardless of whether the claim was later paid on appeal or rebill. Where overlap exists with public datasets, our medians are sanity-checked against published CMS Medicare Advantage performance data and KFF Medicare Advantage enrollment trends to confirm our cohort sits within plus or minus 1 standard deviation of broader industry norms.
The headline finding for 2026 is the persistent and widening gap between Medicare Advantage denial rates and traditional Medicare denial rates. At the median across all specialties in our dataset, MA claims denied at 11.4 percent on first submission. Traditional Medicare claims denied at 5.7 percent over the same observation window. That two-to-one ratio held across nearly every specialty cohort we measured, and the gap widened year over year by roughly 1.1 percentage points relative to our 2025 baseline.
Specialty-level results show wide variance. Primary Care posted the lowest MA denial rate in the dataset at 5.8 percent, supported by simple E/M billing patterns and limited authorization burden. Cardiology came in at 8.2 percent, with most of the elevated rate concentrated in cardiac imaging and electrophysiology procedures. Orthopedics landed at 9.6 percent, driven primarily by physical therapy authorization and DME billing complexity. Oncology recorded 12.7 percent, with denials concentrated in J-code drug claims and step-therapy edits on infusions. Radiology came in at 11.4 percent, with diagnostic imaging carrying the bulk of medical-necessity denials. Behavioral Health posted the highest specialty denial rate at 14.1 percent, driven by carve-out plan complexity, parity-law disputes, and credentialing delays.
For context, the comparable cohort denial rates on traditional Medicare were Primary Care 3.1 percent, Cardiology 4.4 percent, Orthopedics 4.9 percent, Oncology 6.2 percent, Radiology 6.8 percent, and Behavioral Health 7.9 percent. Every specialty saw materially lower traditional-Medicare denial rates than MA. The MA premium on denial rate is not an artifact of one or two outlier plans. It is a structural feature of how Medicare Advantage administers utilization management.
Across the cohort, ten CARC codes accounted for roughly 84 percent of all MA denials. The codes are listed below in volume order, with the percentage of total MA denials attributed to each code in our dataset.
Roughly 38 percent of all MA denials in our dataset. Concentrated in advanced imaging, surgical scheduling, infusion therapy, and physical therapy. Most CARC 197 denials are operational rather than clinical.
Approximately 12 percent. Often paired with RARC codes pointing to missing referring NPI, missing supporting documentation, or invalid demographic fields. The most preventable bucket on this list.
Approximately 9 percent. Concentrated in repeat imaging, cardiac diagnostics, and high-cost infusions. Documentation in the chart frequently supports the service but is not pulled forward into the claim.
Approximately 7 percent. Often appears when a service is carved out to a behavioral-health subcontractor or a specialty pharmacy benefit manager rather than the medical plan itself.
Approximately 5 percent. Frequently triggered by automatic resubmissions before the original claim has finalized, or by mismatched billing locations on the same date of service.
Approximately 4 percent. Tied to ICD-10 specificity at the four or five digit level, especially on cardiac imaging, oncology infusions, and orthopedic injections.
Approximately 3 percent. Common on items the plan considers experimental, investigational, or outside the contracted benefit set.
Approximately 2 percent. Mostly preventable with re-running real-time eligibility at check-in, especially around plan-year boundaries.
Approximately 2 percent. Concentrated in physical therapy, occupational therapy, and behavioral-health visit caps where MA plans apply tighter benefit limits than traditional Medicare.
Approximately 2 percent. Driven by COB record gaps where the MA plan has different primary-payer information than the practice has on file.
Bottom line on the top 10. Authorization (CARC 197), missing information (CARC 16), and medical necessity (CARC 50) together drive roughly 59 percent of all MA denials in our dataset. Practices that prioritize prevention and rework on those three buckets capture the largest share of recoverable revenue.
The top three MA denial drivers in cardiology are CARC 197 on cardiac imaging (stress echo, cardiac MRI, nuclear perfusion), CARC 50 on repeat imaging within a 12-month window, and CARC 11 on diagnosis specificity for chest-pain workups. MA plans have systematically tightened Appropriate Use Criteria edits relative to traditional Medicare, and the denial gap is widest on advanced imaging. Prevention strategy: integrate AUC decision support directly in the order entry workflow, build a payer-by-payer auth matrix for the top imaging CPTs, and capture attestation language in the chart at the point of order.
Top three drivers are CARC 197 on chemotherapy and infusion authorization, CARC 96 on biosimilar substitution and step therapy, and CARC 109 on specialty pharmacy carve-outs. MA plans are aggressive about step therapy on biologics and require pre-treatment fail-first documentation that traditional Medicare does not. Prevention strategy: dedicated benefits-investigation workflow before chemotherapy initiation, J-code-level auth tracking, and a step-therapy override appeal template for each top MA plan.
Top three drivers are CARC 109 on carve-out misrouting, CARC 119 on visit caps, and CARC 197 on therapy-session authorization. Behavioral-health carve-out subcontractors maintain separate enrollment, authorization, and adjudication rules that diverge sharply from medical-plan administration. Prevention strategy: route claims through the carve-out clearinghouse path from day one, track visit counts per patient against payer-specific caps, and pursue retrospective re-billing once individual credentialing closes for delayed-effective-date denials.
Top three drivers are CARC 197 on physical therapy and DME, CARC 11 on diagnosis-procedure pairing for injections, and CARC 96 on PRP and viscosupplementation. Commercial MA plans have tightened experimental-and-investigational policies on regenerative injections through 2025. Prevention strategy: PT auth tracking with visit-count alerts, modifier 25 and 57 documentation discipline on same-day E/M plus procedure encounters, and a clear list of plans that exclude PRP and viscosupplementation so financial counseling can run pre-service.
The recommendations below are ordered by impact on MA recoverable revenue based on our cohort data.
Want a personalized MA denial audit? Revenue Synergy offers a free, no-commitment Medicare Advantage denial pattern audit against this report's benchmarks. We compare your top denial drivers, plan-by-plan, against the cohort medians. Request your audit.
This report measures initial denial rates, not final-disposition denial rates. A meaningful share of CARC 197, 16, and 50 denials are recovered on appeal or correction. Net financial denial impact is therefore lower than the headline denial-rate numbers suggest. The report does not segment by MA plan or geographic region, both of which materially influence denial patterns. National plan benchmarks vary substantially from regional plan benchmarks, and Northeast practices generally see different MA mix dynamics than Sun Belt or West Coast practices. Quarterly refreshes will be published throughout 2026 to track ongoing payer-policy shifts, particularly around Medicare Advantage prior authorization and post-pay audit programs.